Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?
Management of the conventional cardiovascular risk factors is insufficient to prevent the dramatic increase in atherosclerotic cardiovascular morbidity and mortality in patients with renal failure. Folate recently received attention as a potential alternative treatment option to decrease the excess cardiovascular risk in the uremic population. Folate administration is the principal treatment modality for hyperhomocysteinemia. Hyperhomocysteinemia is prevalent in more than 85% of patients with end-stage renal disease (ESRD) and is independently associated with increased odds for atherosclerotic cardiovascular disease. Several attempts have been made to normalize homocysteine levels in uremic patients with folate-based vitamin regimens. Although supraphysiologic doses of folic acid afford greater reductions in homocysteine levels than standard doses, the response to treatment is generally only partial and the large majority of ESRD patients have residual hyperhomocysteinemia. Several def
Related Questions
- How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
- Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?
- Does treatment modality have an impact on anemia in patients with chronic renal failure?
